After FDA nod, Eisai and Biogen file lecanemab in EU

[cafead]

via Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer’s therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in the US late last week.

article source